Market models feeding into the MYGN stock price forecast project stable to mildly bullish trends as volatility index readings in biotech remain lower compared to Q4 last year, calming risk-off attitudes. Promoting a message of body positivity and inclusiveness, Torrid Holdings (NYSE:CURV) is a plus-size women’s apparel and accessories retailer. Research and development expenses rose 10.4% year over year to $27.5 million. SG&A expenses dipped 0.3% to $69 million in the reported quarter. MYGN’s stock price forecast remains constructive due to stable gross margins at 75%, outperforming many mid-cap biotech peers. This pricing power fuels analyst predictions of consistent revenue momentum.